The Value of the 31-GEP for Rural Areas and Health Resource Allocation
Main Article Content
Keywords
31-GEP, Rural Dermatology, melanoma
References
2. Yoo JY, Rigel DS. Trends in dermatology: geographic density of US dermatologists. Arch Dermatol. 2010; 146(7):779. doi: 10.1001/archdermatol.2010.127.
3. Guenther, JM, Ward, A, Martin, BJ. et al. A prospective, multicenter analysis of the integrated 31-gene expression profile test for sentinel lymph node biopsy (i31-GEP for SLNB) test demonstrates reduced number of unnecessary SLNBs in patients with cutaneous melanoma. World J Surg Onc. 2025; 23(1):5. doi: 10.1186/s12957-024-03640-x.
4. Gui J, Guo Z, Wu D. Clinical features, molecular pathology and immune microenvironmental characteristics of acral melanoma. J Transl Med. 2022; 20(1):367. doi: 10.1186/s12967-022-03532-2.
5. Marks E, Wysong A. The 31-gene expression profile test stratifies melanoma-specific survival across histological subtypes in patients with cutaneous melanoma. Poster presented at Fall Clinical October 2025 Las Vegas, NV.
6. Gastman BR, Gerami P, Kurley SJ, Cook RW, Leachman S, Vetto JT. Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria. J Am Acad Dermatol. 2019; 80(1):149-157. doi: 10.1016/j.jaad.2018.07.028.
7. Jarell A, Skenderis B, Dillon LD, Dillon K, Marting B Quick AP, Cook RW. The 31-gene expression profile stratifies recurrence and metastasis in patients with cutaneous melanoma. Future Oncol. 2021;17(36): 5023-5031. doi: 10.2217/fon-2021-0996.
8. Hasanov M, Hasanov E, Pariser D Morgan-Linnell SK, Dierks S, Marting B, Jarell A. The 31-gene expression profile identifies patients at risk of developing early distant metastases and can guide risk-appropriate surveillance strategies. Poster presented at Fall Clinical October 2025 Las Vegas, NV.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.